First U.S. use of CRISPR to directly target cancer will seek goahead from regulators
First U.S. use of CRISPR to directly target cancer will seek go-ahead from regulators
13:57 EDT 2 May 2019 |
STAT
Most trials CRISPR immune cells to attack cancer. If approved, this new one would disable a gene to allow cancer drugs to work better.
More From BioPortfolio on "First U.S. use of CRISPR to directly target cancer will seek go-ahead from regulators"